West New Britain Province (WNBP), Papua New Guinea, implemented a combined four‑drug mass drug administration (MDA) program that included ivermectin, diethylcarbamazine and albendazole (collectively IDA), plus azithromycin. This program represents the first described use in WNBP of this specific four‑drug combination intended to target multiple neglected tropical diseases simultaneously. The study sought to measure the impact of the combined MDA on lymphatic filariasis (LF), scabies, and yaws using both active population surveys and routine passive health‑centre surveillance.
Baseline active surveillance surveyed 43 villages selected using model‑based geostatistics. A total of 3,552 participants were examined at baseline. Diagnostic methods included circulating filarial antigen (CFA) testing and microfilaria (Mf) microscopy to detect LF infections. Standardised skin examinations identified scabies and yaws‑like lesions. Repeat active surveys were conducted in 10 high‑burden villages one year after the MDA to measure change.
Passive surveillance used electronic attendance data from 27 health centres. Monthly attendances for defined diagnostic categories were compared for the six months before and the six months after MDA, enabling comparison of trends in health‑seeking for skin disease and for non‑skin conditions.
At baseline, among 3,552 participants, 151 (4.3%) tested positive for CFA, indicating exposure to or infection with lymphatic filariasis. Microfilaria microscopy detected Mf in 49 participants (1.4%). Skin examinations found scabies in 489 individuals (13.8%) and yaws‑like lesions in 130 individuals (3.6%). These baseline measures established both the community burden of targeted conditions and the sampling frame for follow‑up surveillance in higher‑burden villages.
In the 10 villages surveyed both before and one year after MDA, the active surveillance results showed statistically significant reductions for multiple outcomes:
CFA positivity decreased by 49% (relative risk [RR] 0.51; 95% confidence interval [CI] 0.38–0.70; p<0.0001), falling from 11.5% pre‑MDA to 5.9% post‑MDA.
Microfilaria (Mf) prevalence decreased by 85% (RR 0.15; 95% CI 0.07–0.30; p<0.001), from 4.7% to 0.9%.
Scabies prevalence fell by 78% (RR 0.22; 95% CI 0.14–0.33; p<0.0001), from 11.1% to 2.4%.
Yaws‑like lesions decreased by 31% (RR 0.69; 95% CI 0.41–1.14), from 3.8% to 2.5%; this change did not reach statistical significance (p=0.15).
These results indicate that one round of combined IDA and azithromycin MDA in this setting was associated with large relative declines in parasitological markers of LF and in clinical scabies prevalence, while the reduction in yaws‑like lesions was more modest and not statistically conclusive in the sampled villages.
Electronic data from 27 health centres were analysed to assess healthcare‑seeking changes. Mean monthly attendances for yaws‑like lesions dropped from 27.4 ± 0.9 to 15.5 ± 1.6 after MDA (p<0.0001). Attendances for other skin diseases also decreased, from 95.6 ± 3.4 to 72.9 ± 7.7 (p<0.0001). In contrast, total attendances for non‑skin diseases showed no significant change (728.8 ± 30.9 to 796.8 ± 44.4; p=0.178). These passive surveillance findings support the active survey data by showing reduced clinic presentations for skin conditions following MDA, while general healthcare utilization remained stable.
The study protocol received ethical approval from the Papua New Guinea Medical Research Council (MRAC 22.17) and the Case Western Reserve University Institutional Review Board (STUDY20220661). The authors state that necessary participant consent procedures were followed and relevant approvals obtained. All data produced in the study are available upon reasonable request to the authors. Funding sources declared include Takeda Pharmaceuticals and the Australian National Health and Medical Research Council (grant RG204078).
In this programmatic evaluation in WNBP, a single round of combined ivermectin, diethylcarbamazine, albendazole (IDA) plus azithromycin MDA was associated with substantial reductions in markers and clinical signs of lymphatic filariasis and in prevalence of scabies, with supportive declines in clinic attendances for skin disease. The reduction in clinically suspected yaws cases was smaller and did not reach statistical significance in the repeat‑survey sample.
The study demonstrates the feasibility of delivering a combined four‑drug MDA and of monitoring population impact using a combination of active community surveys and routine health‑centre data. As this report is a preprint, findings have not yet undergone peer review; the authors note that the results should not be used to guide clinical practice without further validation. Detailed data and supplementary materials are available from the authors on request.